RELMADA THERAPEUTICS, INC. (RLMD) Current Ratio
- Current ratio · latest quarter: Value 29.52×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 29.52× | Current assets / current liabilities. $219.04M ÷ $7.42M ≈ 29.52× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 219.04M USD | Assets, Current |
| Current obligations | 7.42M USD | Liabilities, Current |
| Cash and equivalents | 11.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.41M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $219.04M | $7.42M | $11.33M | (m) | (m) | (m) | $2.41M | (m) | 29.52× |
| 2026-03-31 | $235.34M | $12.89M | $9.78M | (m) | (m) | (m) | $5.73M | (m) | 18.26× |
| 2025-12-31 | $93.98M | $6.43M | $3.50M | (m) | (m) | (m) | $1.57M | (m) | 14.62× |
| 2025-09-30 | $14.85M | $5.19M | $1.38M | (m) | (m) | (m) | $1.45M | (m) | 2.86× |
| 2025-06-30 | $21.09M | $5.13M | $1.35M | (m) | (m) | (m) | $1.36M | (m) | 4.11× |
| 2025-03-31 | $27.66M | $5.23M | $1.15M | (m) | (m) | (m) | $1.27M | (m) | 5.29× |
| 2024-12-31 | $45.80M | $10.29M | $3.86M | (m) | (m) | (m) | $4.13M | (m) | 4.45× |
| 2024-09-30 | $55.70M | $8.09M | $1.48M | (m) | (m) | (m) | $2.35M | (m) | 6.89× |
| 2024-06-30 | $70.97M | $9.54M | $2.09M | (m) | (m) | (m) | $4.17M | (m) | 7.44× |
| 2024-03-31 | $84.37M | $12.36M | $1.34M | (m) | (m) | (m) | $5.19M | (m) | 6.82× |
| 2023-12-31 | $97.51M | $12.19M | $4.09M | (m) | (m) | (m) | $3.51M | (m) | 8.00× |
| 2023-09-30 | $109.10M | $8.42M | $6.70M | (m) | (m) | (m) | $2.86M | (m) | 12.95× |
| 2023-06-30 | $122.00M | $10.70M | $14.47M | (m) | (m) | (m) | $4.85M | (m) | 11.40× |
| 2023-03-31 | $135.53M | $10.10M | $28.89M | (m) | (m) | (m) | $4.42M | (m) | 13.42× |
| 2022-12-31 | $152.87M | $12.47M | $5.40M | (m) | (m) | (m) | $5.26M | (m) | 12.26× |
| 2022-09-30 | $187.11M | $20.78M | (m) | (m) | (m) | (m) | $10.43M | (m) | 9.01× |
| 2022-06-30 | $215.74M | $18.92M | (m) | (m) | (m) | (m) | $7.54M | (m) | 11.40× |
| 2022-03-31 | $225.78M | $15.41M | (m) | (m) | (m) | (m) | $10.67M | (m) | 14.65× |
| 2021-12-31 | $223.30M | $15.06M | $44.44M | (m) | (m) | (m) | $11.19M | (m) | 14.83× |
| 2021-09-30 | $90.89M | $18.25M | $11.45M | (m) | (m) | (m) | $12.71M | (m) | 4.98× |
| 2021-06-30 | $110.70M | $13.92M | $4.67M | (m) | (m) | (m) | $10.46M | (m) | 7.95× |
| 2021-03-31 | $103.78M | $12.72M | $3.80M | (m) | (m) | (m) | $8.08M | (m) | 8.16× |
| 2020-12-31 | $118.07M | $12.60M | (m) | (m) | (m) | (m) | $8.35M | (m) | 9.37× |
| 2020-09-30 | $125.47M | $3.39M | $7.54M | (m) | (m) | (m) | $728.63K | (m) | 37.02× |
| 2020-06-30 | $134.40M | $2.33M | $13.82M | (m) | (m) | (m) | $965.17K | (m) | 57.78× |
| 2020-03-31 | $115.25M | $2.26M | $12.23M | (m) | (m) | (m) | $1.10M | (m) | 50.97× |
| 2019-12-31 | $116.94M | $1.46M | $36.28M | (m) | (m) | (m) | $522.66K | (m) | 80.21× |
| 2019-06-30 | $9.98M | $2.61M | $9.22M | (m) | (m) | (m) | $924.36K | (m) | 3.83× |
| 2019-03-31 | $2.33M | $2.13M | $2.05M | (m) | (m) | (m) | $1.08M | (m) | 1.09× |
| 2018-12-31 | $3.03M | $1.86M | $2.43M | (m) | (m) | (m) | $358.89K | (m) | 1.63× |
| 2018-09-30 | $1.27M | $7.10M | $887.49K | (m) | (m) | (m) | $1.02M | (m) | 0.18× |
| 2018-06-30 | $2.74M | $5.90M | $2.24M | (m) | (m) | (m) | $765.44K | (m) | 0.46× |
| 2018-03-31 | $4.48M | $5.54M | $4.26M | (m) | (m) | (m) | $1.09M | (m) | 0.81× |
| 2017-12-31 | $6.24M | $4.57M | $5.94M | (m) | (m) | (m) | $286.06K | (m) | 1.36× |
| 2017-09-30 | $5.27M | $3.47M | $4.68M | (m) | (m) | (m) | $350.54K | (m) | 1.52× |
| 2017-06-30 | $2.47M | $1.38M | $1.71M | (m) | (m) | (m) | $529.56K | (m) | 1.80× |
| 2017-03-31 | $3.24M | $1.23M | $2.76M | (m) | (m) | (m) | $335.43K | (m) | 2.64× |
| 2016-12-31 | $5.30M | $1.41M | $4.71M | (m) | (m) | (m) | $307.24K | (m) | 3.75× |
| 2016-09-30 | $6.97M | $2.21M | $6.22M | (m) | (m) | (m) | $671.72K | (m) | 3.15× |
| 2016-06-30 | $9.30M | $3.06M | $8.50M | (m) | (m) | (m) | $1.26M | (m) | 3.04× |
| 2016-03-31 | $11.78M | $2.40M | $11.35M | (m) | (m) | (m) | $744.16K | (m) | 4.90× |
| 2015-12-31 | $15.66M | $4.78M | $15.13M | (m) | (m) | (m) | $1.69M | (m) | 3.27× |
| 2015-09-30 | $20.05M | $6.65M | $19.17M | (m) | (m) | (m) | $1.15M | (m) | 3.02× |
| 2015-06-30 | $23.97M | $15.58M | $22.47M | (m) | (m) | (m) | $835.28K | (m) | 1.54× |
| 2015-03-31 | $27.81M | $25.26M | $26.96M | (m) | (m) | (m) | $390.37K | (m) | 1.10× |
| 2014-12-31 | $32.76M | $28.10M | $31.42M | (m) | (m) | (m) | $969.95K | (m) | 1.17× |
| 2014-09-30 | $27.82M | $48.47M | $27.39M | (m) | (m) | (m) | $624.73K | (m) | 0.57× |
| 2014-06-30 | $25.74M | $26.77M | $25.56M | (m) | (m) | (m) | $746.10K | (m) | 0.96× |
| 2014-03-31 | $2.56M | $13.91M | $2.46M | (m) | (m) | (m) | $127.09K | (m) | 0.18× |
| 2014-02-28 | $8.75K | $41.16K | (m) | (m) | (m) | (m) | $41.16K | (m) | 0.21× |
| 2013-12-31 | $3.61M | $21.48M | $3.52M | (m) | (m) | (m) | $180.32K | (m) | 0.17× |
| 2013-11-30 | $10.90K | $40.33K | (m) | (m) | (m) | (m) | $40.33K | (m) | 0.27× |
| 2013-08-31 | $18.46K | $33.67K | (m) | (m) | (m) | (m) | $33.67K | (m) | 0.55× |
| 2013-05-31 | $3.03K | $26.03K | (m) | (m) | (m) | (m) | $25.75K | (m) | 0.12× |
| 2013-02-28 | $10.19K | $12.00K | (m) | (m) | (m) | (m) | $12.00K | (m) | 0.85× |
| 2012-12-31 | $1.99M | $5.71M | $1.77M | (m) | (m) | (m) | $237.42K | (m) | 0.35× |
| 2012-08-31 | $18.35K | $7.00K | (m) | (m) | (m) | (m) | $7.00K | (m) | 2.62× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |